Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 13/20 | 0.66 |
| ▸ | FLT3 | P36888 | 10/20 | 0.66 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.66 |
| ▸ | AURKA | O14965 | 5/20 | 0.65 |
| ▸ | CDK9 | P50750 | 5/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.65 |
| ▸ | CDK2 | P24941 | 4/20 | 0.65 |
| ▸ | CDK7 | P50613 | 4/20 | 0.65 |
| ▸ | CDK1 | P06493 | 3/20 | 0.65 |
| ▸ | CDK4 | P11802 | 3/20 | 0.52 |
| ▸ | WEE1 | P30291 | 2/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161732 | 0.92 | AURKA (0.65) | MKNK2FLT3MKNK1AURKACDK9 | |
| SCHEMBL4170533 | 0.85 | MKNK2 (0.64) | MKNK2FLT3MKNK1AURKACDK9 | |
| SCHEMBL4171151 | 0.85 | CDK2 (0.78) | MKNK2FLT3MKNK1AURKACDK9 | |
| SCHEMBL4803155 | 0.84 | CDK2 (0.71) | MKNK2FLT3MKNK1AURKACDK9 | |
| SCHEMBL4165787 | 0.80 | CDK2 (0.77) | MKNK2FLT3MKNK1AURKACDK9 | |
| SCHEMBL4161891 | 0.79 | CDK2 (0.80) | MKNK2FLT3AURKACDK9AURKB | |
| SCHEMBL4154625 | 0.79 | CDK2 (1.00) | MKNK2FLT3MKNK1AURKACDK9 | |
| SCHEMBL2286993 | 0.78 | MKNK2 (0.85) | MKNK2FLT3MKNK1AURKACDK9 | |
| SCHEMBL5621065 | 0.77 | CDK2 (0.69) | MKNK2FLT3MKNK1AURKACDK9 | |
| SCHEMBL4158859 | 0.77 | MKNK2 (0.61) | MKNK2FLT3MKNK1AURKACDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | claimed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | claimed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | MKNK2 330/4885FLT3 618/4885MKNK1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.